Kalaris Q1 net loss $10.2M ($2.52/shr); cash $101M; TH103 Phase 1 data expected Q4 2025

Kalaris Therapeutics, Inc.

2025-Q1 EPS reported -$2.52

Net loss of $10.2M for Q1 2025 vs $3.4M for Q1 2024; diluted EPS loss $2.52.
Cash and equivalents $101.0M as of March 31, 2025, expected to fund operations into Q4 2026.
R&D expenses $6.0M (up from $2.0M YoY) driven by TH103 Phase 1 trial initiation.
Phase 1 trial of TH103 for nAMD actively enrolling; initial clinical data expected Q4 2025.
Completed merger with AlloVir in March 2025; appointed Leone Patterson to Board and Audit Committee.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.